Newsletter | July 29, 2024

07.29.24 -- COVID-19 Concerns Reignite With "FLiRT" Variants

SPONSOR

Partnering with a CDMO with a strong foundation in Cell Line Development (CLD) is essential for biopharma companies looking to efficiently transition a protein from development to commercialization. This article explores key factors in selecting the right CDMO partner for CLD, including expertise in host cell background, preparation for complex protein production, and an emphasis on optimizing and de-risking manufacturing. Additionally, it highlights the importance of effective communication and customer service in fostering successful collaborations.

FEATURED ARTICLE

COVID-19 Is Back: Are We "FLiRT"-ing With Another Disaster?

A combination of vaccine hesitancy and the emergence of new COVID-19 virus strains is prolonging health risks, particularly for older individuals and patients with underlying medical conditions. Vaccine developers must remain committed to updating vaccines and producing better treatments.

SPONSOR

Bioprocess Online is excited to introduce Bio-Expo Live, a series of live virtual events designed to empower biopharma professionals with the chance to conveniently explore the newest equipment and offerings in Upstream Bioprocessing, Downstream Bioprocessing and Bioprocess Quality, Data, and Analytical Solutions. Registration is free, reserve your spot today!

INDUSTRY INSIGHTS

20 Years Of Biosimilars: Are We On The Right Track?

Explore the transformative journey of biosimilars, 20 years in. Through industry expert insights collected from a recent panel discussion, explore regulatory hurdles, market shifts, and the path ahead.

Email: The Gold Standard For Clinical Trials

Although non-verbal conversations between friends are now primarily conducted through text messages or similar apps, see why email remains the standard mode for businesses and organizations.

Put Your AAV On The Fast-Track To The Clinic

Review an innovative method to fast-tracking AAVs through a platform approach that easily scales as the project progresses to late-stage GMP production and to market.

How inSeption Unlocked The Secret To Repeatable, Scalable Low Turnover

This case study explores the evolution of a 10-year partnership and extrapolates the principles that create cohesive teams and minimize turnover.

Cell Line Development For AAV

As advanced therapies race forward, staying ahead is paramount. Harnessing technology, sponsors can unlock efficiencies and propel AAV production to new heights.

Customized Release Through Dispersed Dosage Formats

Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.